Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome
Abstract Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
Subjects: | |
Online Access: | https://doi.org/10.1002/dad2.12057 |
id |
doaj-eefd689289e14cc593bda243f5711e1d |
---|---|
record_format |
Article |
spelling |
doaj-eefd689289e14cc593bda243f5711e1d2021-04-15T14:35:47ZengWileyAlzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring2352-87292020-01-01121n/an/a10.1002/dad2.12057Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndromeRachel L. Henson0Eric Doran1Bradley T. Christian2Benjamin L. Handen3William E. Klunk4Florence Lai5Joseph H. Lee6H. Diana Rosas7Nicole Schupf8Shahid H. Zaman9Ira T. Lott10Anne M. Fagan11Department of Neurology Washington University in St. Louis School of Medicine St. Louis Missouri USADepartment of Pediatrics University of California‐Irvine School of Medicine Irvine California USADepartments of Medical Physics and Psychiatry Waisman Center University of Wisconsin‐Madison Madison Wisconsin USADepartment of Psychiatry University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USADepartment of Psychiatry University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USADepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USAGertrude H. Sergievsky Center Taub Institute for Research in Alzheimer's Disease and the Aging Brain Columbia University New York New York USADepartment of Neurology Massachusetts General Hospital Harvard Medical School Boston Massachusetts USAGertrude H. Sergievsky Center Taub Institute for Research in Alzheimer's Disease and the Aging Brain Columbia University New York New York USADepartment of Psychiatry University of Cambridge Cambridge UKDepartment of Pediatrics University of California‐Irvine School of Medicine Irvine California USADepartment of Neurology Washington University in St. Louis School of Medicine St. Louis Missouri USAAbstract Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS. Methods CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho‐tau181 (p‐tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase‐3‐like protein 1 (YKL‐40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal‐associated protein 25 (SNAP‐25), and visinin‐like protein 1 (VILIP‐1) were assessed in CSF from 44 adults with DS from the Alzheimer's Biomarker Consortium–Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene (APOE) ε4 carrier status. Results Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers. Discussion The profile of many established and emerging CSF biomarkers of AD in a cohort of adults with DS was similar to that reported in LOAD and ADAD, while some differences were observed.https://doi.org/10.1002/dad2.12057Alzheimer's diseasebiomarkerscerebrospinal fluidDown syndromeamyloidtau |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rachel L. Henson Eric Doran Bradley T. Christian Benjamin L. Handen William E. Klunk Florence Lai Joseph H. Lee H. Diana Rosas Nicole Schupf Shahid H. Zaman Ira T. Lott Anne M. Fagan |
spellingShingle |
Rachel L. Henson Eric Doran Bradley T. Christian Benjamin L. Handen William E. Klunk Florence Lai Joseph H. Lee H. Diana Rosas Nicole Schupf Shahid H. Zaman Ira T. Lott Anne M. Fagan Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring Alzheimer's disease biomarkers cerebrospinal fluid Down syndrome amyloid tau |
author_facet |
Rachel L. Henson Eric Doran Bradley T. Christian Benjamin L. Handen William E. Klunk Florence Lai Joseph H. Lee H. Diana Rosas Nicole Schupf Shahid H. Zaman Ira T. Lott Anne M. Fagan |
author_sort |
Rachel L. Henson |
title |
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome |
title_short |
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome |
title_full |
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome |
title_fullStr |
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome |
title_full_unstemmed |
Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome |
title_sort |
cerebrospinal fluid biomarkers of alzheimer's disease in a cohort of adults with down syndrome |
publisher |
Wiley |
series |
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring |
issn |
2352-8729 |
publishDate |
2020-01-01 |
description |
Abstract Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS. Methods CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho‐tau181 (p‐tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase‐3‐like protein 1 (YKL‐40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal‐associated protein 25 (SNAP‐25), and visinin‐like protein 1 (VILIP‐1) were assessed in CSF from 44 adults with DS from the Alzheimer's Biomarker Consortium–Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene (APOE) ε4 carrier status. Results Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers. Discussion The profile of many established and emerging CSF biomarkers of AD in a cohort of adults with DS was similar to that reported in LOAD and ADAD, while some differences were observed. |
topic |
Alzheimer's disease biomarkers cerebrospinal fluid Down syndrome amyloid tau |
url |
https://doi.org/10.1002/dad2.12057 |
work_keys_str_mv |
AT rachellhenson cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT ericdoran cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT bradleytchristian cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT benjaminlhanden cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT williameklunk cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT florencelai cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT josephhlee cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT hdianarosas cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT nicoleschupf cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT shahidhzaman cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT iratlott cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome AT annemfagan cerebrospinalfluidbiomarkersofalzheimersdiseaseinacohortofadultswithdownsyndrome |
_version_ |
1721526374798196736 |